Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -12.21
- Piotroski Score 2.00
- Grade Market Outperform
- Symbol (BCAB)
- Company BioAtla, Inc.
- Price $2.07
- Changes Percentage (3.5%)
- Change $0.07
- Day Low $1.95
- Day High $2.10
- Year High $4.02
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/06/2024
- Fiscal Year End N/A
- Average Stock Price Target $5.00
- High Stock Price Target $5.00
- Low Stock Price Target $5.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.48
- Trailing P/E Ratio -0.61
- Forward P/E Ratio -0.61
- P/E Growth -0.61
- Net Income $-123,462,000
Income Statement
Quarterly
Annual
Latest News of BCAB
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
BioAtla, Inc. (BCAB): Among Michael Burry's Top 10 Stock Picks Heading Into 2025
Scion Asset Management, founded by Michael Burry, focuses on undervalued investments. Burry's recent stock picks include Chinese companies, with a shift towards tech holdings. BioAtla, Inc. is a clini...
By Yahoo! Finance | 2 weeks ago
